Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Depression increases health risks in heart failure patients

28.02.2007
Psychological depression appears to contribute to worse medical outcomes for patients with heart failure, ranking it in importance with such risk factors as high cholesterol, hypertension, and even the ability of the heart to pump blood throughout the body.

After taking into account such factors as disease severity, the strength of the heart muscle contractions, the underlying cause for the heart failure, age and medication use, a team of Duke University Medical Center and University of North Carolina researchers found that symptoms of depression were common in this population, and that depressed patients were over 50 percent more likely to die or be hospitalized for their heart condition than patients who were not depressed.

Heart failure, also known as congestive heart failure, is marked by the inability of the heart muscle to pump enough oxygen and nutrients in the blood to the body’s tissues. A variety of factors can cause heart failure, including infections of the heart, coronary artery disease, high blood pressure, previous heart attacks and a malfunctioning heart valve. An estimated 4.7 million Americans have heart failure, with 400,000 new cases reported each year, and it is the only cardiovascular disease that is rising in incidence, according to the researchers. About half of heart failure patients will die within five years of diagnosis.

"While many studies have linked depression to worse outcomes for patients with heart disease, there has been uncertainty about the extent to which depression is related to the adverse medical outcomes independent of known medical risk factors," said James Blumenthal, Ph.D., co-author of the study and a clinical psychologist at Duke.

The researchers reported the results Monday in the Monday, Feb. 26, 2007 edition of the Archives of Internal Medicine. The study was funded by the National Institutes of Health.

For their study, the researchers enrolled 204 stable heart failure patients. Each patient took a standard battery of psychological tests to assess symptoms of depression. Forty-six percent demonstrated significant depressive symptoms. Patients were followed for an average of three years. During that time, 26 percent died and 48 percent were hospitalized at least once for their heart condition.

What made this analysis different from other such studies was that the researchers coupled the psychological assessment with a relatively new blood test that measures what are known as "B-type natriuretic peptides." These chemicals are released into the bloodstream by the heart tissue when the heart is unable to pump effectively. The chemicals serve as a signal to the kidneys to produce more urine, which in turn reduces the volume of blood fluid, making it easier for damaged or weakened heart muscle to pump blood.

Elevated levels of B-type natriuretic peptides have been previously shown to be associated with increased risk of death for heart attack patients and are now being used in the diagnosis of heart failure.

"As expected, high levels of BNP predicted worse outcomes in our study, but even taken this and other disease makers into account, we found that depressive symptoms were still independently associated with worse outcomes," said study lead investigator Andrew Sherwood, Ph.D., medical psychologist. "Our findings underscore the importance of assessing heart failure patients for depression, so that where treatment is indicated, both the quality and quantity of their lives may be improved.

Researchers still don’t understand why depressed heart patients have worse outcomes. Among possible factors, depressed patients are known to have overly active immune systems, a decrease in the ability of their blood platelets to clot properly and a decrease in their heart’s ability to react appropriately to the stresses of everyday life. Depressed patients also may be less likely to comply with their medical treatments, may not be as motivated to stick with exercise or rehabilitation programs, may miss doctor’s appointments and tend to make unhealthy lifestyle choices in such areas as diet and smoking.

In an attempt to better understand the role of depression in the fate of heart patients, the researchers are currently enrolling patients in a new clinical trial to measure the effects of exercise and antidepressant medications on specific physiological indicators of heart disease. The trial, supported by the National Institutes of Health, has been dubbed UPBEAT -- short for "Understanding the Prognostic Benefits of Exercise and Anti-Depressant Therapy in persons with cardiac disease." Patients with stable coronary disease and symptoms of depression receive 16 weeks of exercise or pill therapy.

The researchers believe that the results of their current analysis, as well as their ongoing trial, will provide guidance for physicians in treating patients with heart failure and coronary artery disease who are also exhibiting signs of depression.

Rebecca Levine | EurekAlert!
Further information:
http://www.mc.duke.edu

More articles from Health and Medicine:

nachricht Improving memory with magnets
28.03.2017 | McGill University

nachricht Graphene-based neural probes probe brain activity in high resolution
28.03.2017 | Graphene Flagship

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Transport of molecular motors into cilia

28.03.2017 | Life Sciences

A novel hybrid UAV that may change the way people operate drones

28.03.2017 | Information Technology

NASA spacecraft investigate clues in radiation belts

28.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>